Literature DB >> 19953636

A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.

Tomoko Nanri1, Naokuni Uike, Toshiro Kawakita, Eisaku Iwanaga, Hiroaki Mitsuya, Norio Asou.   

Abstract

C/EBPalpha plays an essential role as a transcription factor in myeloid cell differentiation. Here, we describe a Japanese family in which two individuals with acute myeloid leukemia (AML) and one healthy individual had an identical 4-base pair insertion in the N-terminal region of CEBPA (350_351insCTAC), resulting in the termination at codon 107 (I68fsX107). The father and a son at diagnosis of AML had different in-frame insertion mutations in the C-terminal region of C/EBPalpha. These C-terminal mutations disappeared upon remission in both patients. Interestingly, the father showed different in-frame insertion mutations in the C-terminal CEBPA at the time of diagnosis and relapse. These data strongly suggest that the N-terminal C/EBPalpha mutation predisposes to the occurrence of a C-terminal C/EBPalpha mutation as a secondary genetic hit, causing AML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19953636     DOI: 10.1002/gcc.20734

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

2.  Index case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation.

Authors:  Jodi Ram; Gabrielle Flamm; Marlene Balys; Umayal Sivagnanalingam; Paul G Rothberg; Anwar Iqbal; Jason R Myers; Anthony Corbett; John M Ashton; Jason H Mendler
Journal:  Blood Adv       Date:  2017-03-14

3.  Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.

Authors:  Anand Pathak; Katja Seipel; Alexander Pemov; Ramita Dewan; Christina Brown; Sarangan Ravichandran; Brian T Luke; Michael Malasky; Shalabh Suman; Meredith Yeager; Richard A Gatti; Neil E Caporaso; John J Mulvihill; Lynn R Goldin; Thomas Pabst; Mary L McMaster; Douglas R Stewart
Journal:  Haematologica       Date:  2015-12-31       Impact factor: 9.941

4.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.

Authors:  John A Pulikkan; Philomina S Peramangalam; Viola Dengler; Phoenix A Ho; Claude Preudhomme; Soheil Meshinchi; Maximilian Christopeit; Oliver Nibourel; Carsten Müller-Tidow; Stefan K Bohlander; Daniel G Tenen; Gerhard Behre
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

Review 5.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

6.  Identification of novel CEBPA double mutations capable of promoting familial AML via the suppression of myeloid differentiation.

Authors:  Yunjing Zheng; Hui Zhang; Qin Lu; Xinran Chu; Li Gao; Peifang Xiao; Jian Pan; Shaoyan Hu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

7.  CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.

Authors:  Katherine Tarlock; Adam J Lamble; Yi-Cheng Wang; Robert B Gerbing; Rhonda E Ries; Michael R Loken; Lisa Eidenschink Brodersen; Laura Pardo; Amanda Leonti; Jenny L Smith; Tiffany A Hylkema; William G Woods; Todd M Cooper; E Anders Kolb; Alan S Gamis; Richard Aplenc; Todd A Alonzo; Soheil Meshinchi
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

8.  The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.

Authors:  Ana Rio-Machin; Tom Vulliamy; Nele Hug; Amanda Walne; Kiran Tawana; Shirleny Cardoso; Alicia Ellison; Nikolas Pontikos; Jun Wang; Hemanth Tummala; Ahad Fahad H Al Seraihi; Jenna Alnajar; Findlay Bewicke-Copley; Hannah Armes; Michael Barnett; Adrian Bloor; Csaba Bödör; David Bowen; Pierre Fenaux; Andrew Green; Andrew Hallahan; Henrik Hjorth-Hansen; Upal Hossain; Sally Killick; Sarah Lawson; Mark Layton; Alison M Male; Judith Marsh; Priyanka Mehta; Rogier Mous; Josep F Nomdedéu; Carolyn Owen; Jiri Pavlu; Elspeth M Payne; Rachel E Protheroe; Claude Preudhomme; Nuria Pujol-Moix; Aline Renneville; Nigel Russell; Anand Saggar; Gabriela Sciuccati; David Taussig; Cynthia L Toze; Anne Uyttebroeck; Peter Vandenberghe; Brigitte Schlegelberger; Tim Ripperger; Doris Steinemann; John Wu; Joanne Mason; Paula Page; Susanna Akiki; Kim Reay; Jamie D Cavenagh; Vincent Plagnol; Javier F Caceres; Jude Fitzgibbon; Inderjeet Dokal
Journal:  Nat Commun       Date:  2020-02-25       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.